Akebia Therapeutics Statistics
Total Valuation
AKBA has a market cap or net worth of $437.85 million. The enterprise value is $470.42 million.
Important Dates
The last earnings date was Monday, November 10, 2025, before market open.
| Earnings Date | Nov 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AKBA has 265.37 million shares outstanding. The number of shares has increased by 20.49% in one year.
| Current Share Class | 265.37M |
| Shares Outstanding | 265.37M |
| Shares Change (YoY) | +20.49% |
| Shares Change (QoQ) | +1.21% |
| Owned by Insiders (%) | 2.01% |
| Owned by Institutions (%) | 48.96% |
| Float | 260.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 24.81 |
| PS Ratio | 1.80 |
| Forward PS | 1.57 |
| PB Ratio | 10.52 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 13.61 |
| P/OCF Ratio | 13.52 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 14.59, with an EV/FCF ratio of 14.62.
| EV / Earnings | n/a |
| EV / Sales | 2.09 |
| EV / EBITDA | 14.59 |
| EV / EBIT | 21.43 |
| EV / FCF | 14.62 |
Financial Position
The company has a current ratio of 1.94, with a Debt / Equity ratio of 4.78.
| Current Ratio | 1.94 |
| Quick Ratio | 1.74 |
| Debt / Equity | 4.78 |
| Debt / EBITDA | 5.34 |
| Debt / FCF | 6.19 |
| Interest Coverage | 0.84 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 4.80% |
| Return on Invested Capital (ROIC) | 9.35% |
| Return on Capital Employed (ROCE) | 9.51% |
| Revenue Per Employee | $1.24M |
| Profits Per Employee | -$87,873 |
| Employee Count | 181 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 1.92 |
Taxes
In the past 12 months, AKBA has paid $615,000 in taxes.
| Income Tax | 615,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.82% in the last 52 weeks. The beta is 0.28, so AKBA's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -7.82% |
| 50-Day Moving Average | 2.60 |
| 200-Day Moving Average | 2.75 |
| Relative Strength Index (RSI) | 30.40 |
| Average Volume (20 Days) | 6,633,740 |
Short Selling Information
The latest short interest is 35.52 million, so 13.38% of the outstanding shares have been sold short.
| Short Interest | 35.52M |
| Short Previous Month | 29.32M |
| Short % of Shares Out | 13.38% |
| Short % of Float | 13.66% |
| Short Ratio (days to cover) | 8.53 |
Income Statement
In the last 12 months, AKBA had revenue of $225.07 million and -$15.91 million in losses. Loss per share was -$0.06.
| Revenue | 225.07M |
| Gross Profit | 187.53M |
| Operating Income | 21.95M |
| Pretax Income | -15.29M |
| Net Income | -15.91M |
| EBITDA | 32.25M |
| EBIT | 21.95M |
| Loss Per Share | -$0.06 |
Full Income StatementBalance Sheet
The company has $166.44 million in cash and $199.01 million in debt, giving a net cash position of -$32.56 million or -$0.12 per share.
| Cash & Cash Equivalents | 166.44M |
| Total Debt | 199.01M |
| Net Cash | -32.56M |
| Net Cash Per Share | -$0.12 |
| Equity (Book Value) | 41.59M |
| Book Value Per Share | 0.16 |
| Working Capital | 124.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $32.40 million and capital expenditures -$223,000, giving a free cash flow of $32.17 million.
| Operating Cash Flow | 32.40M |
| Capital Expenditures | -223,000 |
| Free Cash Flow | 32.17M |
| FCF Per Share | $0.12 |
Full Cash Flow StatementMargins
Gross margin is 83.32%, with operating and profit margins of 9.75% and -7.07%.
| Gross Margin | 83.32% |
| Operating Margin | 9.75% |
| Pretax Margin | -6.79% |
| Profit Margin | -7.07% |
| EBITDA Margin | 14.33% |
| EBIT Margin | 9.75% |
| FCF Margin | 14.30% |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.49% |
| Shareholder Yield | -20.49% |
| Earnings Yield | -3.63% |
| FCF Yield | 7.35% |
Analyst Forecast
The average price target for AKBA is $6.25, which is 278.79% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.25 |
| Price Target Difference | 278.79% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 22.75% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AKBA has an Altman Z-Score of -4.06 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.06 |
| Piotroski F-Score | 5 |
